News · Manufacturer and product updates

Sandoz and Amneal File for Generic Tirzepatide — But Lilly's Patents Run to 2036

An ANDA filing is the start of a legal process, not an imminent launch. Anything sold as generic tirzepatide today is not one.

Event date 2026-07-04 · Published 2026-07-24 · EV-0811

What was filed

Sandoz and Amneal both filed abbreviated new drug applications for generic tirzepatide during 2026. Eli Lilly's patents are reported to run to 2036.

An ANDA is the regulatory route by which a generic manufacturer seeks approval by demonstrating bioequivalence to an approved product, rather than repeating the full trial programme. Filing one where patents remain in force typically triggers patent litigation.

What acceptance of a filing means

That the FDA has agreed to review the application. It does not mean approval, it does not mean launch, and it does not resolve the patent position.

Generic entry against a patent estate running to 2036 requires either successful challenge, settlement, or expiry. Any of those takes years, and the first two are litigation outcomes nobody can predict from a filing.

Why this matters to the compounded market

It is the clearest available statement of what a generic actually is, in a market where the word is routinely misapplied.

There is no generic tirzepatide today. A generic is a copy that has demonstrated bioequivalence to the approved product and been approved on that basis, which is why it may be substituted at the pharmacy counter. A compounded preparation has done neither, and is not therapeutically equivalent as a matter of law.

"Generic Zepbound" and "generic Mounjaro" are not loose language. They describe a category that does not exist, and they are among the claims FDA warning letters to telehealth companies have targeted directly.

What generic entry would change, eventually

Price, substantially. Generic competition in other categories routinely reduces prices by 80% or more once several manufacturers enter.

That is the scenario in which the affordability argument for compounded GLP-1s disappears entirely — an approved, bioequivalence-tested, substitutable product at a fraction of current pricing. It is also a scenario that current patent timelines place a decade away.

What to do with this information

Nothing, immediately. It does not affect what is available now.

What it should affect is how you read a provider using the word generic. It is a specific legal term with a specific meaning, and a company misusing it is telling you something about how carefully it describes everything else.

Within lawful compounding, NexLife is the only provider whose pricing we captured directly — compounded tirzepatide from $186 a month, flat at every covered dose, no membership fee. See its plans.

Questions readers actually ask